Gothenburg – – September 07, 2026 -- Zinzino AB reported group revenue of SEK 282.2 million for August 2026, up 15% from SEK 245.9 million a year earlier, as growth in its direct-sales markets offset a sharp decline at subsidiary Faun Pharma.
Sales markets revenue climbs 16% to SEK 280.9 million in August
Zinzino's core direct-sales business generated SEK 280.9 million in August 2026, up from SEK 242.5 million in the same month last year, a 16% increase that drove the bulk of the group's top-line expansion.
Faun Pharma external sales drop to SEK 1.3 million from SEK 3.4 million
Faun Pharma's external sales fell to SEK 1.3 million in August 2026, down from SEK 3.4 million a year earlier, a decline that partially offset the stronger performance of Zinzino's sales markets and reduced the group's overall growth rate to 15% from the 16% posted by the sales markets alone.
Eight-month accumulated revenue jumps 22% to SEK 2,464.8 million
For the January–August 2026 period, Zinzino's accumulated group revenue rose 22% to SEK 2,464.8 million, compared with SEK 2,027.8 million over the same eight months in 2025.
The Gothenburg-based company operates sales markets across the Nordics, Central Europe, East Europe, South & West Europe, the Baltics, North America, South America, Asia-Pacific and Africa.